SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) October
6, 2005
CHEMBIO
DIAGNOSTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
333-85787
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
| (a) |
On
October 6, 2005, the Registrant issued the press release titled “Chembio
Opens New Business Development Office in West Africa” included herein as
Exhibit 99.1.
|
ITEM
9.01. Financial Statements and Exhibits
(c) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date:
October 6, 2005 Chembio
Diagnostics, Inc.
By: /s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Chembio
Opens New Business Development Office In West Africa
MEDFORD,
N.Y.--(MARKET WIRE)—Oct 6, 2005
Chembio
Diagnostics Inc. today announced the opening of a new business development
office in West Africa in Abuja, Nigeria as part of its strategy to market HIV
tests to countries which are recipients of the President’s Emergency Plan for
AIDS Relief (PEPFAR) program. Dr. Joseph Nnorom, MD, MPH, until most recently
the Medical Epidemiologist of the CDC’s Global AIDS Program in Nigeria, will
head up these operations.
Dr.
Nnorom’s twenty years experience in public health as a medical epidemiologist
encompasses implementation, monitoring and evaluation of HIV/AIDS/ STI and
reproductive health programs. “Joseph’s program management experience in
Voluntary Counseling and Testing (VCT), Prevention of Mother to Child
Transmission (PMTCT), anti-retroviral therapy (ART) and treatment monitoring
of
AIDS cases will be an enormous asset to Chembio, helping us with our sales
and
marketing efforts in Africa. We are delighted to have a local presence in
Nigeria,” said Avi Pelossof, Chembio’s VP of Sales, Marketing and Business
Development.
“This
opportunity will allow me to be used more effectively in the public health
arena, a calling close to my heart and to the benefit of all individuals,
families and communities confronted with HIV/AIDS” said Dr. Nnorom. With
governmental and non-governmental agencies taking a stance to improve treatment
in this AIDS ravaged region, Dr. Nnorom will play a vital role in Chembio’s
efforts to supply the region with its rapid HIV 1/2 Stat-Pak test. “Dr. Nnorom’s
long and illustrious career in public health combined with his leadership roles
with the CDC, UNICEF, USAID and the Federal Ministry of Health will provide
an
impetus to the battle against HIV/AIDS” said Larry Siebert, Chembio’s Chairman
and President.
Chembio’s
rapid HIV tests include the HIV 1/2 Stat-Pak, HIV 1/2 Stat-Pak Dipstick and
the
HIV 1/2 Sure Check ™. All three tests are simple, safe, cost-effective and
operator-friendly requiring less than five microliters of blood from a
fingerstick. The HIV 1/2 Stat-Pak and the Sure Check ™ are currently under
review by the FDA.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc. (Chembio) possesses expertise in the development and
manufacturing of rapid test products for various infectious diseases, including
HIV, Tuberculosis and Chagas Disease. References to Chembio Diagnostics, Inc.
may actually refer to Chembio Diagnostic Systems, Inc., the 100%-owned
subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock
Road, Medford, NY 11763. Chembio's telephone number is 631-924-1135. Email
can
be directed to info@chembio.com.
Additional information can be found at www.chembio.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited
to,
the Company's ability to obtain additional financing and the demand for the
Company's products. The Company undertakes no obligation to publicly update
these forward-looking statements to reflect events or circumstances that occur
after the date hereof or to reflect any change in the Company's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events.
Contact:
Maya
Wagle, Director of Investor Relations
mwagle@chembio.com
631-924-1135/ext. 125
Source:
Chembio Diagnostics, Inc.